Edition:
United Kingdom

Evotec AG (EVTG.DE)

EVTG.DE on Xetra

14.43EUR
20 Apr 2018
Change (% chg)

-- (--)
Prev Close
€14.43
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,467,049
52-wk High
€22.50
52-wk Low
€10.35

Chart for

About

Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees,... (more)

Overall

Beta: 0.67
Market Cap(Mil.): €3,115.81
Shares Outstanding(Mil.): 147.49
Dividend: --
Yield (%): --

Financials

  EVTG.DE Industry Sector
P/E (TTM): 82.62 84.02 32.74
EPS (TTM): 0.26 -- --
ROI: 11.42 1.58 14.38
ROE: 13.87 2.41 16.07

BRIEF-Evotec Says Endometriosis Programme With Bayer Moves To Phase I Development

* DGAP-NEWS: EVOTEC AND BAYER ADVANCE THIRD ENDOMETRIOSIS PROGRAMME INTO PHASE I CLINICAL DEVELOPMENT Source text for Eikon: Further company coverage:

18 Apr 2018

BRIEF-Evotec AG Says ‍Plans Conversion Into European Company​

* SAYS ‍PLANS CONVERSION INTO EUROPEAN COMPANY​ Source text for Eikon: Further company coverage: (Reporting by Frankfurt Newsroom)

27 Mar 2018

Sanofi, Evotec team up for research on infectious diseases treatment

PARIS Sanofi and Evotec said they had started exclusive talks over accelerating research into the treatment of infectious diseases, and added on Thursday that they would form a new open innovation platform in this area, led by Evotec.

08 Mar 2018

BRIEF-Evotec, Apeiron Biologics receive milestone payment from Sanofi

* SAYS ‍EVOTEC AND APEIRON ACHIEVE FIRST MILESTONE IN IMMUNO-ONCOLOGY ALLIANCE WITH SANOFI​

08 Jan 2018

BRIEF-Evotec receives milestone payment from Boehringer Ingelheim​

* SAYS ‍EVOTEC RECEIVES CLINICAL MILESTONE AS PART OF ITS DISCOVERY ALLIANCE WITH BOEHRINGER INGELHEIM

01 Dec 2017

BRIEF-Evotec affirms guidance after 9-month core profit jump

* ‍9M adjusted group EBITDA up 28% to eur 39.3 m (9m 2016: eur 30.6 m)​

08 Nov 2017

BRIEF-Evotec, Tesaro enter partnership on novel immuno-oncology agents

* dgap-news: evotec and tesaro enter strategic partnership to discover novel immuno-oncology agents

26 Oct 2017

Earnings vs. Estimates